|
業務類別
|
Biotechnology |
|
業務概覽
|
Veraxa Biotech Holding AG is an oncology-focused biotechnology company. It is engaged in advancing the development of novel antibody-based drug platforms for the treatment of cancer. The Company originates from scientific discoveries made at the European Molecular Biology Laboratory. The Company's proprietary platform technologies enable the development of new generations of effective, targeted antibody-based cancer therapies. Such developments enable the Company to accelerate a pipeline of next-generation cancer therapies that have the potential to expand the therapeutic window of current solid tumor standard of care treatments through improved safety and efficacy profiles. |
| 公司地址
| Talacker 35, Zurich, CHE, 8001 |
| 電話號碼
| +41 443858450 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.veraxa.com |
| 員工數量
| 3 |
| Dr. Heinz Schwer, PhD |
Chief Business Officer; Chief Business Officer and Managing Director of VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Mr. Torsten Buergermeister |
Chief Financial Officer of the Company and VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Dr. Rick Austin, PhD |
Chief Scientific Officer of VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Dr. Christoph Antz, PhD |
Chief Executive Officer of the Company and VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Dr. Christoph Erkel, PhD |
Vice President and Head of Preclinical Development of VERAXA Biotech GmbH |
-- |
31/07/2025 |
|
|
| Mr. Oliver R. Baumann |
Chairman of the Board |
19/02/2026 |
| Mr. Marc Gruninger |
Independent Director |
19/02/2026 |
| Mr. Christoph Ziegler |
Independent Director |
19/02/2026 |
| Mr. David L. Deck |
Independent Director |
31/07/2025 |
| Dr. Warren Hosseinion, M.D. |
Independent Director |
19/02/2026 |
|
|
|
|
